

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 23291

Title: Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with HCV

Reviewer's code: 01562153

Reviewer's country: Taiwan

Science editor: Jing Yu

Date sent for review: 2015-11-09 09:49

Date reviewed: 2015-11-22 14:16

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this manuscript, the author reported the treatment of daclatasvir and asunaprevir in 4 cases of chronic hepatitis C patients with hemodialysis. The authors found that one patient had viral breakthrough and the 3 others had sustained virologic response, and that only one patient was admitted for heart failure and the combination therapy was well tolerated in the other 3 patients. This is a retrospective observational study on the combination therapy of daclatasvir and asunaprevir in 4 cases of chronic hepatitis C patients with hemodialysis, the originality of this manuscript is not high. However, this article can provide some useful information for the clinicians for managing chronic hepatitis C patients with end stage renal disease. Comments 1. The Section of Case Report is too redundant. This part should be condensed. 2. The authors should provide the severity of liver disease of these patients, e.g. severity of fibrosis. 3. The authors should not treat the patient No.1, because they had found the existence of resistance associated virus (RAV) before treatment. The authors should not treat the patient just because the patient had a strong desire to receive treatment. 4. Some spelling errors should be corrected, e.g. sustained virologic response (not sustained



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

virological response), resistance associated virus (not resistance associated viral resistance), etc.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 23291

Title: Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with HCV

Reviewer's code: 00071472

Reviewer's country: Indonesia

Science editor: Jing Yu

Date sent for review: 2015-11-09 09:49

Date reviewed: 2015-11-30 10:03

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [Y] Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> [] High priority for publication
<input checked="" type="checkbox"/> [Y] Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> [Y] No	<input type="checkbox"/> [] Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> [Y] No	

COMMENTS TO AUTHORS

Comments: The authors reported combination therapy with daclatasvir and asunaprevir for four dialysis patients infected with HCV genotype 1b. Except for one patient which was discontinued after viral breakthrough, this combination therapy was quite effective, however long term observation and monitoring of patients should be done. Overall, this combination therapy was well tolerated in patients. This case report will be useful as a base for further investigate the effectiveness of the combination therapy of daclatasvir and asunaprevir in dialysis patients. However, extensive study should be done in order to establish guideline for application of direct-acting antiviral agents (DAAs) in dialysis patients infected with HCV. Although there is no guidance for application of DAAs in dialysis patients, it is much better if the authors explain the reasons why they discontinued this combination therapy in case 1.